Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04211259 · ClinicalTrials.gov registry record · Early Phase 1
Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
A Early Phase 1 study, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 70
- Enrollment target
NCT04211259 is a Early Phase 1 study that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 70 participants.
The verdict
NCT04211259, a Early Phase 1 study, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or control bone pain during the process of stem cell collection in patients with multiple myeloma.
Interventions
- OTHER Placebo
- OTHER Questionnaire Administration
- DRUG Loratadine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2022-04-18 |
| Est. Completion | 2027-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04211259
The ClinicalTrials.gov registry entry for NCT04211259 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04211259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04211259 about?
NCT04211259 is a clinical study titled "Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization". This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or control bone pain during the p...
What is the current status of trial NCT04211259?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 70 participants. The study started on 2022-04-18. Estimated completion is 2027-06-30.
What interventions are being tested in trial NCT04211259?
The interventions under investigation include: Placebo (OTHER), Questionnaire Administration (OTHER), Loratadine (DRUG).
Who is sponsoring clinical trial NCT04211259?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.